Completed Chemistry Cells, Biochemistry & Physiology

Chemogenomics.

In plain English

AI plain-English summary

A private company’s trove of drug-discovery data is moving to a public database, giving academic researchers free access to information that was previously locked behind commercial walls. These pharmacological structure-activity-relationship (SAR) data describe how drug-like molecules interact with their biological targets. Until now, academic labs could only find such data piecemeal in the literature or buy it from commercial vendors, which has held back their ability to engage in effective drug discovery. Without this resource, many promising target-compound relationships remain unexplored outside industry. The team will transfer the data to the European Bioinformatics Institute, build a searchable database, and provide web access, programmatic interfaces, and downloads. They will also establish a curation pipeline and integrate the data with other biological resources at EBI. Training programmes will help academic scientists exploit the data for translational research. If successful, this resource could accelerate target identification for all diseases—including neglected tropical diseases that lack commercial markets—enable knowledge-based lead optimisation, and improve the design of chemical libraries. In the longer term, it could also support better predictive toxicology, quietly strengthening the drug-development infrastructure that underpins modern medicine.

View original technical description
This proposal seeks support to transfer a world class chemogenomic data resource from the private sector (BioFocus DPI/Galapagos) to the public domain and maintain it at the European Bioinformatics Institute. These pharmacological structure-activity-relationship (SAR) data characterise target-ligand interactions and provide the starting point for chemical biology and the knowledge-based design of lead molecules and their optimisation to viable drugs. To date such data have only been available pi ecemeal in the literature or commercially, and this has inhibited the engagement of academic laboratories in effective drug discovery. In this proposal our key goals are to secure the SAR data for the public domain; to establish the target-compound structure activity (SAR) database at EBI; to provide access to these data for life scientists through the web, through programmatic interfaces and by download; to establish a robust update pipeline, including manual curation; to integrate these data w ith other biological data resources at EBI and to promote exploitation of these data for translational research in academia by providing training. Such data will enable improved target identification for all diseases, including neglected third-world diseases, knowledge-based lead identification and optimisation, the design of smarter chemical libraries and in the future improved predictive toxicology.

View the original record at the funder ↗

Researchers

Janet Thornton (EPMC Awardee)

Related Research

Grants with similar aims, by meaning.

The ChEMBL database
The ChEMBL Database An Open Resource for Drug Discovery
Building a Next Generation Image Repository: Molecular Annotation and Cloud-based Data Processing and Analysis
Accelerating drug discovery through a networked structural biology resource
A UK Hub to Catalyse Open Target Discovery.

Original classification

Strategic Award - Science

Plain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research.